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Abstract
Using Bayes’ Theorem, we derive generalized equations to determine the positive
and negative predictive value of screening tests undertaken sequentially. Where a is
the sensitivity, b is the specificity, φ is the pre-test probability, the combined positive
predictive value, ρ(φ), of n serial positive tests, is described by:
ρ(φ) =
φ
n∏
i=1
an
φ
n∏
i=1
an + (1− φ)
n∏
i=1
(1− bn)
(1)
If the positive serial iteration is interrupted at term position ni− k by a conflicting
negative result, then the resulting negative predictive value is given by:
ψ(φ) =
[(1− φ)bn−]
b(n−1)+∏
i=b1+
(1− bn+)
[φ(1− an−)]
a(n−1)+∏
i=a1+
an+ + [(1− φ)bn−]
b(n−1)+∏
i=b1+
(1− bn+)
(2)
Finally, if the negative serial iteration is interrupted at term position ni − k by a
conflicting positive result, then the resulting positive predictive value is given by:
λ(φ) =
φan+
a(n−1)−∏
i=a1−
(1− an−)
φan+
a(n−1)−∏
i=a1−
(1− an−) + [(1− φ)(1− bn+)]
b(n−1)−∏
i=b1−
bn−
(3)
The aforementioned equations provide a measure of the predictive value in different
possible scenarios in which serial testing is undertaken. Their clinical utility is best
observed in conditions with low pre-test probability where single tests are insufficient
to achieve clinically significant predictive values and likewise, in clinical scenarios
with a high pre-test probability where confirmation of disease status is critical.
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1 Predictive Value of Screening Tests
The concepts of positive ρ(φ) and negative σ(φ) predictive value lie at the core of
clinical diagnostics [2]. The positive predictive value is defined as the probability that
an individual with a positive screening test does indeed have the disease tested for.
Conversely, the negative predictive value is the probability that an individual with a
negative screening test does not in fact have the disease tested for [3]. In technical
terms, where T is true, F is false, P is positive, N is negative, a is the sensitivity, b is the
specificity and φ is the disease prevalence/pre-test probability, the positive predictive
value ρ(φ) of a screening test is defined following Bayes’ Theorem as:
PPV = ρ(φ) =
TP
TP + FP
=
aφ
aφ+ (1− b)(1− φ)
(4)
Likewise, the negative predictive value σ(φ) is defined as:
NPV = σ(φ) =
TN
TN + FN
=
b(1− φ)
φ(1− a) + b(1 − φ)
(5)
Moreover, we denote the false negative rate (FNR) as the compliment of the sensi-
tivity, and the false positive rate (FPR) as the compliment of the specificity [5], such
that:
FNR = 1− a =
FN
FN + TP
(6)
FPR = 1− b =
FP
FP + TN
(7)
For the purposes of the concepts henceforth discussed, it is critical to understand that the
FNR represents actual cases misdiagnosed as being disease-free, and the FPR represents
disease-free cases diagnosed as having the condition in question. Since it is the actual
underlying status of the patient that is relevant to the predictive value equations then
we need to consider true negatives and false positives (and vice-versa) as belonging to
the same group since the underlying disease status is the same in each case. These have
the following epidemiological definitions:
True negatives =
{
TN = specificity = b
FP = 1− specificity = 1− b
True positives =
{
TP = sensitivity = a
FN = 1− sensitivity = 1− a
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1.1 Properties of Predictive Curves
As per Bayes’ theorem, ρ(φ) and σ(φ) are prevalence-dependent. It thus follows
that the reliability of screening tests is prevalence-dependent as well. We have shown
in previous work that a testing system’s predictive ability can tolerate significant drops
in prevalence/pre-test probability, up until a certain well-defined inflection point known
as the prevalence threshold, φe, below which the reliability of a positive screening test
drops precipitously [1]. This is independent of the adequacy and reliability of the test
and thus implies inherent Bayesian limitations to the screening process itself.
φe =
√
a (−b+ 1) + b− 1
(a+ b− 1)
(8)
Fortunately, sequential testing overcomes the aforementioned Bayesian limitations [1].
Indeed, in order to attain a desired positive predictive value of ρ that approaches k, the
number of serial positive test iterations needed, for a single test carried out repeatedly,
as per the tablecloth [1] function is:
ni = lim
ρ→k


ln
[
ρ(φ−1)
φ(ρ−1)
]
ln
[
a
1−b
]

 (9)
where ni = number of testing iterations necessary to achieve ρ, the desired positive
predictive value, and k = constant such that 0 < k < 1.
2 Orthogonal Testing
We define orthogonal testing in the screening context as the serial application of sta-
tistically independent screening tests to enhance the positive and/or negative predictive
value. In comparison to the tablecloth function, which applies a singular test serially,
orthogonal testing is carried out when two or more different tests that screen for the
same condition are carried out in subsequent order. Using Bayes’ Theorem we can de-
rive a formula to determine the positive and negative predictive values using orthogonal
testing. Where D = disease, ¬D = no disease, T = positive test, ¬T = negative test,
the expression of Bayes’ theorem in generalized terms for the presence of disease in the
presence of a positive test is the following:
P (D|T ) =
P (T |D)P (D)
P (T |D)P (D) + P (T |¬D)P (¬D)
(10)
Likewise, for the absence of disease with a negative test, we obtain:
P (¬D|¬T ) =
P (¬T |¬D)P (¬D)
P (¬T |¬D)P (¬D) + P (¬T |D)P (D)
(11)
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Theorem 1. Let T1, T2, ..., Tn denote n independent, positive tests, such that
P (T1, T2, ...Tn) = [P (T1|D)P (T2|D)...P (Tn|D)]P (D) + [P (T1|¬D)...P (Tn|¬D)]P (¬D).
Since the sensitivity a = P (T |D) and specificity b = P (¬T |¬D) such that
P (T |¬D) = 1-b, then, as per Bayes’ Theorem, the expression for P (D|T1, T2, ..., Tn) is:
P (D|T1, T2, ...Tn) =
P (T1, T2...Tn|D)P (D)
P (T1, T2...Tn|D)P (D) + P (T1, T2...Tn|¬D)P (¬D)
In terms of screening parameters, the above equation therefore becomes:
ρ(φ) =
a1...anφ
a1...anφ+ (1− b1)...(1 − bn)(1 − φ)
=
φ
n∏
i=1
an
φ
n∏
i=1
an + (1− φ)
n∏
i=1
(1− bn)
(12)
where an is the test-specific sensitivity, bn is the test-specific specificity and n is the
number of serial tests undertaken. The above follows from the law of total probability.
Of importance, this equation allows for the calculation of the positive predictive value
only in cases of serial positive tests carried out orthogonally. Visually, we can observe the
effects that orthogonal testing with serial positive tests has on the positive predictive
value curve for three independent, positive tests T1, T2, T3 of varied sensitivity and
specificity parameters:
0 0.2 0.4 0.6 0.8 1
0
0.2
0.4
0.6
0.8
1
φ
ρ
(φ
)
T1+
T1+ · T2+
T1+ · T2+ · T3+
From the above relationship, we observe that as serial different positive tests are ac-
counted for, we reach the limit of ρ(φ) = 1, as set by the fundamental theorem of
screening [2]:
lim
n→∞
ρn(φ) = lim
a+b→2
∫ 1
0
ρ(φ)dφ = 1 (13)
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3 Sequential Testing
When faced with a given clinical scenario amenable to screening, one may calculate
ni to determine the number of serial positive tests needed to obtain a desired positive
predictive value, particularly if the prevalence or pre-test probability is low. As dis-
cussed, the latter can be accomplished by utilizing a single test serially, in which case
the tablecloth equation (9) applies, or by undertaking orthogonal testing with two or
more tests serially, in which case the generalized equation in (12) applies. The level of
predictive value opted for will depend on the particular disease being screened for, and
the degrees of comfort with Type 1 and Type 2 errors that one is willing to incur [4].
A type I error is the rejection of a true null hypothesis (also known as a false positive
finding or conclusion), while a type II error is the non-rejection of a false null hypothesis
(also known as a false negative finding or conclusion)[4]. What happens if during a finite
sequence S of positive test (t) iterations, be it from a single test or different tests, one
stumbles upon a negative test prior to attaining the desired positive predictive value?
S = {t±}
ni
t=0 = {t1+, t2+, t3−, ...ni}
First, from a purely probabilistic standpoint, in cases where σ(φ) >> ρ(φ), it follows
that in the absence of strictly positive serial results, we consider the presence of a neg-
ative test as dominant and come to the conclusion that the individual tested is in fact
unlikely to have the disease. That said, what if ρ(φ) ∽ σ(φ) after ni - k tests? With
contradictory orthogonal tests we can calculate the negative predictive value through
the following formula, ψ(φ), derived from Bayes’ Theorem by modifying the equation in
(5) in cases where σ(φ) > ρ(φ). The derivation stems directly from Theorem 1 as above.
ψ(φ) =
(1− b1+)(1− b2+)...(1− bn+)(1− φ)b−
a1+a2+...φ(1− a−) + (1− b1+)(1− b2+)...(1− bn+)(1− φ)b−
(14)
where ax+ and bx+ are the sensitivity and specificity of the xth positive test and ax−
and bx− are the like parameters of the interjecting negative test. Since in this case we
undertake serial testing to enhance the positive predictive value, it is implied that σ(φ)
> ρ(φ). Therefore, the above equation ψ(φ) is a modification of σ(φ) and provides a
revised measure of the negative predictive value. The above equation is simplified as:
ψ(φ) =
[(1− φ)bn−]
bn−1+∏
i=b1+
(1− bn+)
[φ(1− an−)]
an−1+∏
i=a1+
an+ + [(1− φ)bn−]
bn−1+∏
i=b1+
(1− bn+)
(15)
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4 Domain Partitions of Geometric Spaces
In graphic form, the predictive value equations are displayed as follows, with the
positive predictive curve in blue, and the negative predictive curve in red:
0 0.2 0.4 0.6 0.8 1
0
0.2
0.4
0.6
0.8
1
φ
ρ
(φ
),
σ
(φ
)
ρ(φ)
σ(φ)
ρ, σ = 1
As depicted above, both predictive value curves are continuous, and have domains
[0-1] and ranges [0-1]. These curves intersect at a single point within the domain, which
is defined as a function of parameters in (4) and (5). In effect, this intersection point, φi,
partitions the geometric space pi(φ) of the predictive curves into two areas: a negative-
dominant partition (NDP) and a positive-dominant one (PDP). The negative-dominant
partition splits the domain of the geometric space to such values where σ(φ) > ρ(φ),
and vice-versa such that:
pi(φ) =


NDP if σ(φ) > ρ(φ), dom = [0, φi(
0 if σ(φ) = ρ(φ), dom = [φi]
PDP if σ(φ) < ρ(φ), dom = )φi, 1]
Analytically, we determine the area of partition by obtaining the difference in the definite
integral of each curve to and from the intersection point φi, such that:
NDP =
∫ φi
0
σ(φ)dφ−
∫ φi
0
ρ(φ)dφ (16)
PDP =
∫ 1
φi
ρ(φ)dφ−
∫ 1
φi
σ(φ)dφ (17)
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4.1 Intersectionality φi of the Predictive Curves
We can determine the prevalence/pre-test probability level φi where the predictive
curves intersect by equating formulas (4) and (5) and isolating φ:
aφ
aφ+ (1− b)(1− φ)
=
b(1− φ)
φ(1− a) + b(1 − φ)
(18)
Breaking up the fractions:
aφ[φ(1− a) + b(1− φ)] = [aφ + (1− b)(1− φ)][b(1− φ)] (19)
Expanding the parentheses:
aφ[(φ− aφ) + (b− bφ)] = [aφ+ (1− φ− b+ bφ)](b− bφ) (20)
Re-arranging the terms:
aφ(φ− aφ) + aφ(b− bφ) = aφ(b− bφ) + (b− bφ)(1− φ− b+ bφ) (21)
Removing aφ(b− bφ) on either side:
aφ(φ− aφ) = (b− bφ)(1− φ− b+ bφ) (22)
We can expand the equations to obtain:
aφ2 − a2φ2 = b− bφ− b2 + b2φ− bφ + bφ2 + b2φ− b2φ2 (23)
Factoring out φ:
(a− b− a2 + b2)φ2 + (2b− 2b2)φ− (b− b2) = 0 (24)
We thus obtain a simple quadratic equation of the form ax2+bx+c = 0, the solution
of which is given by the following relationship: −b±
√
b2−4ac
2a , provided a
2− b2−a+ b 6= 0,
which would imply a = b. Given that the domain of the predictive value function is
[0,1], we take the negative value of the rooted term to determine the intersection that
falls within the domain.
φi =
−b2 + b−
√
ab (ab− a+ 1− b)
a2 − b2 − a+ b
(25)
Should a tests’ sensitivity and specificity be equal, we can overcome nullity in the
denominator of (25) by increasing the specificity b by db to obtain an approximate
estimation of the intercept point.
b⇒ b+ db (26)
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4.2 Graphic Representation of Geometric Partitions
Graphically, we depict the geometric partitions of the screening curves as follows, in
an example case where a = 0.80 and b = 0.95, and where the NDP is represented in red
and the PDP in blue:
0 0.2 0.4 0.6 0.8 1
0
0.2
0.4
0.6
0.8
1
φ
ρ
(φ
),
σ
(φ
)
We can thus see that equation (12) applies well when we seek to enhance the positive
predictive value in cases where the pretest probabilities lie in the NDP area. What if
in contrast we wanted to enhance the negative predictive value of a test for a condition
whose pre-test probability lies beyond φi, in the PDP? Using Bayes’ theorem, we need
to now modify the σ(φ) equation in (5). Once again, following the same derivation as
depicted in Theorem 1, this time for P (¬T |¬D), we obtain:
σ(φ) =
(1− φ)
n∏
i=1
bn
(1− φ)
n∏
i=1
bn + φ
n∏
i=1
(1− an)
(27)
With this in mind, what happens if during a finite sequence R of negative test (t)
iterations, be it from a single test or different tests, one stumbles upon a positive test
prior to attaining the desired negative predictive value?
R = {t±}
ni
t=0 = {t1−, t2−, t3+, ...ni}
Akin to all the derivations previously discussed in this work, the ensuing positive
predictive value is described by the following equation:
λ(φ) =
(1− a1−)(1− a2−)...an+φ
(1− a1−)(1− a2−)...an+φ+ b1−b2−...(1 − bn+)(1− φ)
(28)
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where ax− and bx− are the sensitivity and specificity of the xth negative test and ax+
and bx+ are the like parameters of the positive test. Simplified, the equation becomes:
λ(φ) =
φan+
a(n−1)−∏
i=a1−
(1− an−)
φan+
a(n−1)−∏
i=a1−
(1− an−) + [(1− φ)(1− bn+)]
b(n−1)−∏
i=b1−
bn−
(29)
5 Conclusion
The equations derived in this work provide deductive, quantitative proofs regarding
the impact of sequential and orthogonal testing on the predictive value of screening tests
in different clinical scenarios where screening is undertaken. Their clinical utility is best
observed in conditions with low pre-test probability where single tests are insufficient to
achieve clinically significant predictive values and likewise, in clinical scenarios with a
high pre-test probability where confirmation of disease status is critical. Application of
the methods herein described in clinical situations is needed to provide empirical proof
of their validity and usefulness.
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